AllianceBernstein’s C4 Therapeutics CCCC Stock Holding History

AllianceBernstein’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$170K	Buy	+64,780	New	+$222K	﹤0.01%	3187
2025 Q2	–	Sell	-47,800	Closed	-$76.5K	–	3248
2025 Q1	$76.5K	Hold	47,800	–	–	﹤0.01%	3092
2024 Q4	$172K	Hold	47,800	–	–	﹤0.01%	3051
2024 Q3	$272K	Buy	47,800 +2,020	+4%	+$12.2K	﹤0.01%	2955
2024 Q2	$212K	Buy	+45,780	New	+$273K	﹤0.01%	3014
2023 Q2	–	Sell	-52,000	Closed	-$163K	–	3181
2023 Q1	$163K	Hold	52,000	–	–	﹤0.01%	2956
2022 Q4	$307K	Buy	52,000 +4,300	+9%	+$35.7K	﹤0.01%	2860
2022 Q3	$418K	Sell	47,700 -3,100	-6%	-$32.2K	﹤0.01%	2729
2022 Q2	$383K	Sell	50,800 -93,921	-65%	-$826K	﹤0.01%	2794
2022 Q1	$3.51M	Buy	144,721 +42,154	+41%	+$1.02M	﹤0.01%	1759
2021 Q4	$3.3M	Buy	102,567 +21,370	+26%	+$845K	﹤0.01%	1843
2021 Q3	$3.63M	Buy	81,197 +19,915	+32%	+$853K	﹤0.01%	1781
2021 Q2	$2.32M	Buy	+61,282	New	+$2.19M	﹤0.01%	2110

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AllianceBernstein's CCCC Position: Q2 2026 in Review

AllianceBernstein opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 64,780 shares worth $170K. The stake represents ﹤0.01% of the portfolio and ranks #3187 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in CCCC as recently as Q1 2025.

AllianceBernstein first reported a position in CCCC in Q2 2021 and has held it in 13 quarters since. The position peaked at $3.63M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

AllianceBernstein held 64,780 shares of C4 Therapeutics worth $170K as of Q2 2026.
C4 Therapeutics was a new AllianceBernstein position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3187 holding.
AllianceBernstein first reported a position in C4 Therapeutics in Q2 2021 and has held it in 13 quarters since.
AllianceBernstein's C4 Therapeutics position peaked at $3.63M in Q3 2021.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.